NSE: APOLLOHOSP | BSE: 508869

Mid-range Performer

Download real time

7411.50 -76.00 (-1.02%)

52W high on Oct 23, 2025

150.4K NSE+BSE Volume

NSE 18 Nov, 2025 12:38 PM (IST)

106,566

Market Cap

Market Runner Up

0.8

Beta 1Year

Very Low volatility

Apollo Hospitals Enterprise Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APOLLOHOSP, BSE:508869 Apollo Hospitals Enterprise Ltd.

Search Inside the pdf :

Apollo Hospitals Enterprise Ltd.

10 Nov 2025

7411.50

-1.02%

Apollo Hospitals Enterprise (APHS IN) Q2FY26 Result Update ...

Buy: Apollo Hospitals Enterpris...

Prabhudas Lilladhar

Number of MF schemes increased from 324 to 349 in Sep 2025 qtr.

Apollo Hospitals Enterprise Ltd.

09 Nov 2025

7411.50

-1.02%

Soft quarter; bed addition critical to revive growth in hospitals

Hold: Apollo Hospitals Enterpris...

Target

ICICI Securities Limited

Apollo Hospitals’ (Apollo) hospital biz grew slower at ~9% YoY in Q2FY26, though in line with our expectations. On a high base, occupancy declined to 69% in Q2 while lower international patients and few medical admissions also had an impact.

Apollo Hospitals Enterprise Ltd. is trading below its 30 day SMA of 7722.0

Apollo Hospitals Enterprise Ltd.

08 Nov 2025

7411.50

-1.02%

Improved case mix/Healthco drives earnings

Buy: Apollo Hospitals Enterpris...

Target

Motilal Oswal

Apollo Hospitals Enterprises (APHS) delivered largely in-line revenue for the quarter. It delivered better-than expected EBITDA/PAT, led by improved profitability in the hospitals/Healthco business.

Number of MF schemes increased from 324 to 349 in Sep 2025 qtr.

Apollo Hospitals Enterprise Ltd.

07 Nov 2025

7411.50

-1.02%

Apollo Hospitals

Buy: Apollo Hospitals Enterpris...

Recommendation Target

ICICI Direct

Q2FY26 Results- well-rounded growth with continued margin expansion- Revenues grew ~13% YoY to 6303 crore, driven by growth across segments. EBITDA grew 15% to 941 crore and EBITDA Margins improved 34 bps to 14.9%, driven by improved profitability at AHLL (Diagnostic and Retail Healthcare) and Healthcare Services (Hospitals). Healthcare services division (Hospitals) revenues grew 9% YoY to 3169 crore on the back of growth in Inpatient Volume (up 2%) and 7% increase in Price & case...

Promoters unpledged 4.53% of shares in last quarter. Total pledge stands at 8.58% of promoter holdings

Apollo Hospitals Enterprise Ltd.

14 Aug 2025

7411.50

-1.02%

Apollo Hospitals Enterprise (APHS IN) Q1FY26 Result Update ...

Buy: Apollo Hospitals Enterpris...

Target

Prabhudas Lilladhar

Apollo Hospitals Enterprise (APHS) reported consolidated EBITDA of Rs8.5bn (up 26% YoY), was 6% above our estimates. Adjusted for 24x7 losses and ESOPs cost (~Rs1.2bn), EBITDA was Rs9.7bn, up 18% YoY. The recent stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business complemented by the fastgrowing omni-channel digital health business. Scale-up in Apollo HealthCo has been on track with likely breakeven in EBITDA of digital business over the next 3-4 quarters. The management guidance of Rs20bn EBITDA of the merged entity by FY28 provides comfort. Further, mgmt. has also announced the...

Prabhudas Lilladhar released a Buy report for Apollo Hospitals Enterprise Ltd. with a price target of 9300.0 on 10 Nov, 2025.

Apollo Hospitals Enterprise Ltd.

02 Jul 2025

7411.50

-1.02%

Apollo Hospitals Enterprise (APHS IN) Event Update Demerger...

Buy: Apollo Hospitals Enterpris...

Target

Prabhudas Lilladhar

to ensure non-compete and synergy alignment between AHEL and NewCo, with clear role demarcation - AHEL to focus on core healthcare and NewCo on pharmacy & digital. The demerger was on expected lines and is aimed to unlock value by creating a focused, high-growth platform in the pharmacy and digital healthcare space, which is more consumer centric in nature. The stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business. Scale-up in...

Apollo Hospitals Ent.. has an average target of 8598.40 from 5 brokers.

Apollo Hospitals Enterprise Ltd.

01 Jul 2025

7411.50

-1.02%

Strategic demerger sets stage for long-term value creation

Buy: Apollo Hospitals Enterpris...

Target

Motilal Oswal

The proposal to demerge the pharmacy business—including offline pharmacy, online and telehealth operations, and Kiemed—into NewCo bodes well for longterm value creation across both the healthcare services (hospital/clinics business) and pharmacy businesses.

Promoters unpledged 4.53% of shares in last quarter. Total pledge stands at 8.58% of promoter holdings

Apollo Hospitals Enterprise Ltd.

16 Jun 2025

7411.50

-1.02%

APOLLO HOSPITAL

Accumulate: Apollo Hospitals Enterpris...

Recommendation Target

Geojit BNP Paribas

Under HealthCo, offline pharmacy revenue grew 16.6% YoY to Rs. 2,084cr as store count rose to 6,626 (vs 6,360 in Q3FY25) and strong private-label sales. Online pharmacy sales grew 22.3% YoY to Rs. 292cr. Apollo got a boost as daily active...

Apollo Hospitals Enterprise Ltd. is trading above its 200 day SMA of 7160.0

Apollo Hospitals Enterprise Ltd.

01 Jun 2025

7411.50

-1.02%

Apollo Hospitals Enterprise (APHS IN) Q4FY25 Result Update ...

Buy: Apollo Hospitals Enterpris...

Prabhudas Lilladhar

Apollo Hospitals Enterprise (APHS) reported consolidated EBITDA of Rs7.7bn (up 20% YoY), was in line with our estimates. Adjusted for 24x7 losses and ESOPs cost (~Rs1.6bn), EBITDA was Rs9.3bn, up 18% YoY. The recent stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business complemented by the fastgrowing omni-channel digital health business. Scale-up in Apollo HealthCo has been on track with likely breakeven in EBITDA of digital business over the next...

Prabhudas Lilladhar released a Buy report for Apollo Hospitals Enterprise Ltd. with a price target of 9300.0 on 10 Nov, 2025.

Apollo Hospitals Enterprise Ltd.

31 May 2025

7411.50

-1.02%

Operationally in-line 4Q; ends FY25 on a strong note

Buy: Apollo Hospitals Enterpris...

Target

Motilal Oswal

Apollo Hospitals Enterprises (APHS) posted marginally better-than-expected revenue (4% beat), while EBITDA was in line for the quarter. The lower tax rate led to better-than-expected earnings for the quarter.

Apollo Hospitals Enterprise Ltd. is trading above its 200 day SMA of 7160.0

Is Apollo Hospitals Enterprise Ltd. worth buying?

232 Votes:

Buy 70.69%

Sell 20.69%

Hold 8.62%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf